Quince Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022
August 04 2022 - 7:00AM
Business Wire
Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical
company advancing innovative precision therapeutics targeting
debilitating and rare diseases, today announced that the company’s
chief executive officer Dirk Thye, M.D., will present at the
Canaccord Genuity 42nd Annual Growth Conference taking place on
Thursday, August 11, 2022 beginning at 9:00 a.m. Eastern Time. A
live webcast of the event will be accessible on the Investor
Calendar page under the News & Events heading of Quince’s
Investor Website. The webcast will be archived at that location for
90 days.
About Quince Therapeutics
Quince Therapeutics is focused on advancing innovative precision
therapeutics targeting debilitating and rare diseases. The company
discovered a broad bone-targeting drug platform designed to
precisely deliver small molecules, peptides, or large molecules
directly to the site of bone fracture and disease to promote more
rapid healing with fewer off-target safety concerns compared to
non-targeted therapeutics. Quince’s discovery pipeline is
positioned for rapid expansion across multiple skeletal therapeutic
indications to address underserved therapeutic areas with major,
unmet medical needs, including osteogenesis imperfecta, fractures,
spinal fusion, and other severe bone diseases. The company’s lead
compound NOV004 is an anabolic peptide engineered to precisely
target and concentrate at the bone fracture site, which preclinical
studies demonstrate result in rapid increases in bone density,
strength, and healing directly at the site of bone fracture. NOV004
is expected to enter Phase 1 clinical studies in 2023 and advance
to a lead indication in osteogenesis imperfecta. For more
information, visit www.quincetx.com and follow Quince Therapeutics
on LinkedIn and @Quince_Tx on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220804005361/en/
Quince Therapeutics Contact: Stacy Roughan Quince
Therapeutics, Inc. Vice President, Corporate Communications &
Investor Relations ir@quincetx.com
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Apr 2024 to May 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From May 2023 to May 2024